Articles

Evidence of protective effects of recombinant ADAMTS13* in humanized model for sickle cell disease

Baxalta Innovations GmbH, a Takeda company, Vienna
Dept of Medicine, University of Verona and Azienda Ospedaliera Universitaria Integrata di Verona, Policlinico GB Rossi, Verona
Dept of Medicine, University of Verona and Azienda Ospedaliera Universitaria Integrata di Verona, Policlinico GB Rossi, Verona
Baxalta Innovations GmbH, a Takeda company, Vienna
Baxalta Innovations GmbH, a Takeda company, Vienna
Baxalta Innovations GmbH, a Takeda company, Vienna
Baxalta Innovations GmbH, a Takeda company, Vienna
Baxalta Innovations GmbH, a Takeda company, Vienna, Austria; Dipartimento di Medicina Molecolare e Biotecnologie Mediche, Università degli Studi di Napoli Federico II, and CEINGE Biotecnologie Avanzate, Naples
Baxalta Innovations GmbH, a Takeda company, Vienna
Baxalta Innovations GmbH, a Takeda company, Vienna
Baxalta Innovations GmbH, a Takeda company, Vienna
Dipartimento di Medicina Molecolare e Biotecnologie Mediche, Università degli Studi di Napoli Federico II, and CEINGE Biotecnologie Avanzate, Naples
Dipartimento di Medicina Molecolare e Biotecnologie Mediche, Università degli Studi di Napoli Federico II, and CEINGE Biotecnologie Avanzate, Naples
Baxalta Innovations GmbH, a Takeda company, Vienna
Baxalta Innovations GmbH, a Takeda company, Vienna
Baxalta Innovations GmbH, a Takeda company, Vienna
Baxalta Innovations GmbH, a Takeda company, Vienna
Dept of Medicine, University of Verona and Azienda Ospedaliera Universitaria Integrata di Verona, Policlinico GB Rossi, Verona
Haematologica Early view Apr 21, 2022 https://doi.org/10.3324/haematol.2021.280233